Clinical Trial Update: A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. [Phase 2]

View source ↗

Summary

Phase II trial evaluating camrelizumab plus famitinib as adjuvant therapy for stage II-IIIA non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC | Phase 2 | Status: UNKNOWN